← All trials
NCT05838885
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 15, 2022
- Primary completion
- Dec 31, 2023
- Completion date
- Mar 31, 2024
- First posted
- May 3, 2023
- Last posted
- May 3, 2023
- Enrollment
- 78
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Xiamen Amoytop Biotech Co., Ltd.Lead sponsor
- Huazhong University of Science and TechnologyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.